Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas

Inclusion Criteria: * Histologic diagnosis of unresectable or metastatic soft tissue sarcoma * Measurable disease outside of a prior irradiated area * ECOG performance status 0,1, or 2. * 0 or 1 prior regimens for advanced disease. * Adequate end organ function, defined as bilirubin \< 1.8; SGOT/SGPT \< 2.5 x upper limit of normal (ULN); creatinine \< 1.5 x ULN. * Negative pregnancy test * Life expectancy of greater than 3 months Exclusion Criteria: * Patient has received any investigational agents within 28 days of first day of study drug dosing * Two or more prior regimens for advanced disease * Prior gemcitabine or vinorelbine * Another primary malignancy * Grade III/IV cardia dysfunction * Female patients who are pregnant or breast-feeding * Severe and/or life-threatening medical disease * Known diagnosis of HIV infection * Prior chemotherapy within 4 weeks prior to study entry * Major surgery within 2 weeks prior to study entry * Known hypersensitivity to either gemcitabine or vinorelbine